DGAP-News: Sangui BioTech International Inc.: - Sales of USD 11,272 in the first quarter - Mölnlycke takes over distribution of Granulox

Sangui BioTech:

- Sales of USD 11,272 in the first quarter

- Mölnlycke takes over distribution of Granulox

Witten, November, 15, 2018: In the first three months of fiscal year 2019 (to 30/06/2019) Sangui BioTech International Inc. achieved revenues from royalty income of USD 11,272. In the same period of the previous year the comparable revenue amounted to USD 16,636. Due to decreased revenues of the wound spray Granulox, the resulting royalty income in the first three months decreased by 32% compared to the same period of the previous year.

Operating expenses increased USD 30,276 or 41% to USD 104,697 during the period. This was mainly due to higher costs for consulting and general administration. The operating loss for the first three months increased by USD 35,709 to USD 93,498 compared to the same period last year.

On July 2, 2018, Mölnlycke Health Care GmbH acquired all shares of SastoMed GmbH. The associated scheduled restructuring was mainly responsible for the decline in Granulox's sales in the quarter under review. Over the coming months, the Mölnlycke Group has given priority to increasing the sales volume of Granulox.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.